FDA approves Baxalta's treatment for common bleeding disorder

(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Baxalta Inc's Vonvendi, making it the first engineered protein-based treatment for the world's most common inherited bleeding disorder.